Introduction. Acute respiratory viral infections in children remain an urgent problem, not only because of the high incidence, but also a significant contribution to the mortality structure of young children. Approaches to the treatment of acute respiratory viral infections are considered, taking into account the possibility of the impact of drugs on the main links of pathogenesis and prevention of complications from the perspective of a bioregulatory approach to therapy and complex bioregulatory drugs.The purpose of the study. To present the effectiveness of bioregulatory therapy of respiratory viral infections in children from the perspective of clinical and pathogenetic aspects of the disease.Materials and methods. A pro- and retrospective study was conducted for 2 years of 70 sick children aged 6 to 12 years with acute respiratory infections of moderate severity. The patients were observed in the homeopathic center “Homeopathic Medicine” in Samara.Results. Improvement in children was observed by day 3 of the disease in patients receiving bioregulatory therapy (group 1) and by day 5 in children receiving conventional therapy (group 2) for respiratory infections (temperature and well-being normalized, intoxication syndrome was stopped). Remission of the disease occurred in 72% of group 1 children on day 5 of the disease and on day 6–7 in 47% of group 2 children. Taking Engystol® in tablets for 1 month after recovery allowed to reduce the number of relapses by almost 3 times during the year compared with children of group 2 who did not receive bioregulatory drugs.Discussion. With a moderate course of respiratory infections, it is possible to use the drugs Girel, Viburcol®, Engystol® without the use of allopathic remedies, which significantly reduces the drug load on the body of a sick child and prevents the development of undesirable reactions.Conclusions. The effectiveness, safety, and good tolerability of the drugs Girel, Viburcol®, and Engystol® are confirmed by their own results. These drugs can be recommended for use in pediatric practice in respiratory viral infections.

No abstract

No abstract

No abstract